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Abstract: In addition to good mechanical properties needed for three-dimensional tissue 
engineering, the combination of alginate dialdehyde, gelatin and nano-scaled bioactive 
glass (45S5) is supposed to combine excellent cellular adhesion, proliferation and 
differentiation properties, good biocompatibility and predictable degradation rates. The 
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goal of this study was to evaluate the in vitro and in vivo biocompatibility as a first step on 
the way to its use as a scaffold in bone tissue engineering. In vitro evaluation showed good 
cell adherence and proliferation of bone marrow derived mesenchymal stem cells seeded 
on covalently crosslinked alginate dialdehyde-gelatin (ADA-GEL) hydrogel films with and 
without 0.1% nano-Bioglass® (nBG). Lactate dehydrogenase (LDH)- and mitochondrial 
activity significantly increased in both ADA-GEL and ADA-GEL-nBG groups compared 
to alginate. However, addition of 0.1% nBG seemed to have slight cytotoxic effect 
compared to ADA-GEL. In vivo implantation did not produce a significant inflammatory 
reaction, and ongoing degradation could be seen after four weeks. Ongoing vascularization 
was detected after four weeks. The good biocompatibility encourages future studies using 
ADA-GEL and nBG for bone tissue engineering application. 
Keywords: alginate dialdehyde; gelatin; nano-Bioglass®; tissue engineering; 
biocompatibility; mesenchymal stem cells 
 
1. Introduction 
Alginate is a polysaccharide found in brown seaweeds (Laminaria sp., Macrocystis sp., Lessonia sp. 
and others). The ability to form hydrogels in the presence of calcium ions that can be easily modulated 
into various shapes, the good in vitro and in vivo biocompatibility, low toxicity and its low price make 
alginate a promising candidate for tissue engineering applications [1–4]. However, alginate shows a 
low viscosity, making precise 3D printing difficult [2]. Furthermore, it does not degrade, but rather 
dissolves in surrounding physiological media of mammals and remains in the body [5]. Another 
limitation is that it does not promote cell interactions [6], which is a crucial feature in  
tissue engineering.  
One possibility for overcoming these limitations is covalent crosslinking of alginate and gelatin. 
Gelatin is obtained by acidic or basic hydrolysis of collagen, a substance found in the extracellular 
matrix (ECM). Its use has been shown to promote cell adhesion and proliferation in vitro [7,8]. 
Furthermore increase in gelatin content results in a higher viscosity of the hydrogel thus making it 
more suitable for three-dimensional tissue engineering applications [2].  
Both alginate and gelatin have shown good biocompatibility in numerous in vivo studies with and 
without encapsulated cells [4,9–11]. Gelatin has been shown to promote angiogenesis [10], an 
important feature in tissue engineering, where survival of cells in large implants depends on formation 
of new blood vessels. In addition good osteogenesis has been observed when using alginate/gelatin 
scaffolds in bone tissue engineering [11].  
Bioactive glasses are increasingly considered in bone tissue engineering due to their  
angiogenic [12] and osteogenic [13] properties. Recently, nano-scaled bioactive glass particles (nBG) 
have been integrated into various biopolymers, such as alginate [14], gelatin [15], collagen [16] and 
chitosan [17–19]. Stimulation of osteogenic cell proliferation and differentiation [20] and formation of 
bone-like apatite clusters [19] have been observed. Due to their higher specific surface, nano-scaled 
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particles are likely to show faster solubility, higher protein adsorption and therefore higher bioactivity 
than larger particles [21]. 
To the best of our knowledge, this is the first study evaluating the biocompatibility of covalently 
crosslinked alginate dialdehyde-gelatin hydrogel with and without nBG in vitro and in vivo, as well as 
degradation and vascularization behavior of these materials after subcutaneous implantation in rats. 
2. Methods 
2.1. In vitro: Preparation of Hydrogels 
2.1.1. Materials 
Sodium alginate (derived from brown algae, suitable for immobilization of micro-organisms, 
guluronic acid content 65%–70%), gelatin (Bloom 300, Type A, porcine skin, suitable for cell culture) 
were purchased from Sigma-Aldrich (Munich, Germany). Sodium metaperiodate and calcium chloride  
di-hydrate (CaCl2 2H2O) were purchased from VWR international (Leuven, Belgium). 45S5 nBG was 
synthesized by flame pyrolysis [21] and received from ETH (Zurich, Switzerland). The composition of 
the nanosized bioactive glass is 47.8 wt% SiO2, 25.1 wt% CaO, 22.6 wt% Na2O, and 4.6 wt% P2O5. 
The particle size of nBG is in the range of 20–60 nm [22]. 
2.1.2. Synthesis of Alginate Dialdehyde-Gelatin Crosslinked (ADA-GEL) and Alginate Hydrogels 
The synthesis process of ADA-GEL hydrogel was elaborately described in our previous study [23]. 
Shortly, ADA-GEL hydrogel was synthesized by covalent crosslinking of alginate dialdehyde (ADA) 
and gelatin. ADA was synthesized by controlled oxidation of sodium alginate with sodium 
metaperiodate (oxidizing agent) in equal volume of ethanol-water mixture. After 6 h the reaction was 
quenched by adding ethylene glycol (VWR int., Leuven, Belgium) and dialyzed against ultrapure 
water (Direct-Q®, Merck Millipore, Darmstadt, Germany) using a dialysis membrane (MWCO:  
6000–8000 Da, Spectrum Lab, Rancho Dominguez, CA, USA) for 7 days and then lyophilized. 
Gelatin solution (5% w/v, in water) was added slowly in ADA solution (5% w/v, in phosphate 
buffered saline (PBS)) under continuous stirring to facilitate crosslinking between ADA and gelatin.  
To prepare alginate solution, sodium alginate 2% (w/v) was dissolved in PBS and the prepared 
solution was sterilized by filtration using 0.45 µm filter. 
2.1.3. Preparation of Films 
ADA and gelatin solution were sterilized by filtration through 0.45 µm and 0.22 µm filter (Carl 
Roth GmbH + Co. KG, Karlsruhe, Germany), respectively, prior to mixing. Sterilized ADA and 
gelatin solutions were mixed in equal volume ratio. nBG particles were sterilized by dry heat 
sterilization technique. Sterilized nBG particles were added to ADA solution prior to mixing with 
gelatin to prepare ADA-GEL-nBG hydrogels that contained 0.1% (w/v) nBG.  
Alginate, ADA-GEL and ADA-GEL-nBG hydrogels were casted in sterile petridishes. Ionic 
gelation of the casted films was conducted with calcium chloride (CaCl2) solution (0.1 M). Serum free 
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco®, Darmstadt, Germany) was used to wash the 
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hydrogel films and cut by punching to make the films of desired size and shape (circular, diameter 
13.5 mm and thickness 1.5 mm). 
For the in vitro study, ADA-GEL and ADA-GEL-nBG hydrogels along with alginate (control 
hydrogel) was used. 
2.2. Isolation and Cultivation of MSCs 
Bone-marrow derived mesenchymal stem cells (MSCs) were isolated from an adult male Lewis rat. 
The animal was deeply anesthetized using isoflurane in pure oxygen, and both femora and tibiae were 
aseptically explanted. Each bone marrow cavity was flushed with 15 mL MACS buffer (PBS, 
Biochrom + 2% fetal calf serum, Biochrom, Berlin, Germany), and the resulting cell suspension was 
centrifuged at 1400 rpm for 4 min. The supernatant was discarded and the cell pellet resuspended in 
culture medium (DMEM + Ham’s F12 1:1, Biochrom, Berlin, Germany; 20% FCS, Biochrom, Berlin, 
Germany; 1% L-Glutamine, Gibco, Darmstadt, Germany). The cell pellet was filtered through a  
100 µm pore size cell strainer (BD, Heidelberg, Germany). Mononuclear cells were isolated using 
density gradient centrifugation (Histo-Paque 1077, Sigma Aldrich, Munich, Germany). Cells were 
seeded on a standard plastic 24 well plate (Greiner Bio-One, Frickenhausen, Germany) with 2 × 106 
cells/well. After 36 h, the non-adherent cells were removed by washing each well with PBS, and fresh 
medium was supplied.  
Cells were monitored daily, and medium was changed every 2–3 days; passaging was done at  
70%–80% confluency (after 5–6 days). Cells were detached using trypsin/EDTA solution (Biochrom, 
Berlin, Germany) for 4 min, and seeded at 5000 cells/cm² (P1, P2) or 3000 cells/cm² (P3 and following 
passages) onto standard plastic cell culture flasks (Greiner Bio-One, Frickenhausen, Germany).  
2.3. In Vitro Cell Attachment and Proliferation Studies: 2D 
The prepared circular films of alginate, ADA-GEL and ADA-GEL-nBG hydrogels were transferred 
into a 24-well plates (VWR int., Leuven, Germany). MSCs were seeded at a density of 100,000 
cells/film, cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco®, Darmstadt, Germany) 
supplemented with 10% (v/v) fetal calf serum (FCS) (Sigma-Aldrich, Munich, Germany) and 1% (v/v)  
penicillin-streptomycin (Gibco®, Darmstadt, Germany) and incubated in a humidified atmosphere of 
95% relative humidity and 5% CO2, at 37 °C. Culture medium was changed the day after seeding and 
then every two days. 
2.3.1. Mitochondrial Activity 
Mitochondrial activity of seeded MSCs on different hydrogel films was assessed through the 
enzymatic conversion of tetrazolium salt (WST-8 assay kit, Sigma Aldrich, Munich, Germany) after 
48 h of cultivation. Culture medium was completely removed from the incubated films and 1% (v/v) 
WST-8 assay kit containing culture medium was subsequently added and incubated for 2 h. 100 µL of 
supernatant from each samples were transferred into a 96 well-plate and the absorbance at 450 nm was 
measured with a microplate reader (PHOmo, autobio labtec instruments co. Ltd., Zhengzhou, China). 
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2.3.2. Lactate Dehydrogenase (LDH) Activity 
A commercially available LDH-activity quantification kit (TOX7, Sigma-Aldrich, Munich, 
Germany) was used to quantify the LDH enzyme activity in cell lysate. After 48 h of incubation the 
hydrogel films were washed with PBS, and lysis buffer was added to the films (1 mL/film) and 
incubated for 30 min. Lysates were centrifuged at 2000 rpm for 5 min and 140 µL from the 
supernatant solutions were transferred to 1 mL cuvettes. 60 mL of master-mix (equal amounts of 
substrate solution, dye solution, and cofactor solution for LDH assay) were added to each cuvette and 
incubated for 30 min. The reaction was stopped with 300 µL of 1N HCl, and 500 µL of water were 
added. The absorbance of each solution was measured at 490 and 690 nm using a UV-Vis 
spectrophotometer (Specord 40, Analytik Jena AG, Jena, Germany). 
2.3.3. Fluorescence Staining 
To reveal the morphology of the adhered cells after 48 h of cultivation, staining was performed with 
Rhodamine Phalloidin (Invitrogen, Carlsbad, CA, USA), which selectively stains F-actin. Nuclei were 
stained with green nucleic acid stain, SYTOX® (Invitrogen, Carlsbad, CA, USA). Phalloidin-Sytox 
stained MSCs on hydrogel films were visualized by fluorescence microscopy (FM) (Axio Scope A.1, 
Carl Zeiss Microscopy, Jena, Germany). 
2.3.4. Cell Counting 
The cell number was identified by counting DAPI-stained cell nuclei using ImageJ software 
(National Institutes of Health, Bethesda, MD, USA; version 1.47v). Four images of 20× magnification 
from different areas of each film were used to define the cell uniformity of the film. The entire area of 
image was calculated and the number of cells was presented per unit area of sample. 
2.4. In vivo: Subcutaneous Implantation of ADA-GEL Microcapsules 
2.4.1. Animals 
In vivo procedures were approved by the government of Middle Franconia and the according 
Animal Protection Committee (Az 54-2532.1-24/09). 
Six adult, healthy male Lewis rats (weight 303–320g) were used. In each animal, two chambers 
filled with pure ADA-GEL microcapsules and two chambers filled with ADA-GEL + nano-Bioglass® 
(nBG) microcapsules were implanted. Time until explantation was 1 week (3 animals) and 4 weeks (3 
animals). Six chambers per group and per explantation point were evaluated. Animals were housed in 
single cages (type 3) in a standardized environment (20–22 °C, relative humidity 46%–48%, light/dark 
cyclus of 12 h), and had free access to water and standard chow (Ssniff, Soest, Germany).  
2.4.2. In Vivo Implantation 
Microcapsules were prepared immediately before subcutaneous implantation. For the  
in vivo study, we selected the materials with best results from in vitro analysis (ADA-GEL and  
ADA-GEL-nBG). Solutions were prepared as described for in vitro experiments. Microcapsules from 
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ADA-GEL and ADA-GEL-nBG hydrogels were prepared by pneumatic extrusion technique. 
Hydrogels were transferred into an extrusion cartridge (Nordson EFD, East Providence, RI, USA), 
which was connected to a high precision fluid dispenser (Ultimus V, Nordson EFD, East Providence, 
RI, USA). Microcapsules were generated by applying different air pressure (2.3 bars to 2.5 bars), 
collected in a beaker containing CaCl2 solution (0.1 M) and kept for 10 min to allow for ionic gelation. 
Subsequently the fabricated microcapsules were sieved and washed three times with medium (DMEM) 
to remove calcium chloride solution from the surface of the microcapsules. After the crosslinking 
procedure, microcapsules were transferred into custom made Teflon chambers for subcutaneous 
implantation (inner diameter 8 mm, height 6 mm, volume approx. 400 µL; Figure 1a). Weight of 
chambers filled with microcapsules was approximately 300 mg. 
Figure 1. (a) Teflon chambers filled with ADA-GEL microcapsules prior to implantation. 
Inner diameter of chambers = 8 mm; (b) Subcutaneous implantation of Teflon chambers. 
 
Rats were anesthetized using an induction chamber filled with 5% isoflurane in oxygen. After 
induction, rats were placed on a heating plate and anesthesia was maintained by delivering isoflurane 
(Isofluran, CP Pharma, Burgdorf, Germany) in oxygen via face mask. Preemptive analgesia was 
achieved by administration of 0.03 mg/kg buprenorphin (Temgesic, RB Pharmaceuticals, Mannheim, 
Germany). A single administration of procain penicillin (22000 IU/kg) and dihydrostreptomycin  
(50 mg/kg) (Veracin compositum, Albrecht, Aulendorf, Germany) was used for prevention  
of infection.  
Rats were placed in sternal recumbency, and the back was clipped and aseptically prepared for 
surgery. Two paramedian, longitudinal incisions were created on the back, and subcutaneous tissue 
was removed to expose the underlying muscle. Two chambers were placed on each side with the open 
side facing downwards, thus bringing the microcapsules in direct contact with the muscle (Figure 1b). 
Chambers were fixed using USP 4/0 polypropylene (Prolene, Ethicon; Johnson&Johnson, Norderstedt, 
Germany) sutures, and the skin was closed using USP 4/0 polyglactin 910 (Vicryl Plus, Ethicon; 
Johnson&Johnson, Norderstedt, Germany). Buprenorphin treatment was continued until the second 
postoperative day, followed by administration of tramadol (Tramal, 100 mg/mL, Gruenenthal, Aachen, 
Germany) via drinking water (7.5 mg/100 mL of tap water) for the first postoperative week.  
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2.4.3. Explantation Procedure 
After 1 and 4 weeks, respectively, rats were anesthetized as described above. Animals were placed 
in dorsal recumbency, and a midline laparotomy was performed. Intestines were exteriorized, and the 
caudal vena cava and aorta were isolated. A 24 G vein cannula was inserted into the caudal vena cava, 
the aorta was opened, and the vascular system was flushed with heparinized saline solution. After 
removing all blood from the vessels, a mixture of India Ink (Lefranc-Bourgeois; Colart Deutschland 
GmbH, Maintal, Germany; 20 mL), saline solution (0.9%; 20 mL), mannite (Carl Roth GmbH & Co 
KG, Karlsruhe, Germany; 1.2 g) and gelatin (Carl Roth GmbH & Co KG, Karlsruhe, Germany; 1.5 g) 
was injected. After cooling at −20 °C for 2 h, chambers were explanted and fixed in 4% formaldehyde 
solution (Histofix 4%, Carl Roth GmbH & Co KG, Karlsruhe, Germany) for 24 h. Microcapsules were 
carefully removed from the teflon chambers with the underlying muscle and further processed for 
routine histology.  
2.4.4. Histological Evaluation 
Three micrometer cross sections were obtained from two standardized planes (1 mm left and 1 mm 
right of the central plane) rectangular to the longitudinal axis of the construct. Hematoxylin and eosin 
(H&E) staining was performed according to standard protocols. Immunohistological stainings were 
performed for ED1 (detection of macrophages/immune reaction) and Lectin (Bandeiraea Simplicifolia 
agglutinin, BS-1; endothelial cells). 
Lectin. Paraffinated sections were dewaxed and cooked in citrate buffer (pH 6) for 1 min at 121 °C. 
After 10 min in 3% H2O2 (Merck, Darmstadt, Germany), sections were incubated in avidin and biotin 
blocking solution (Avidin/Biotin Blocking Kit, Vector Labs; Biozol, Eching, Germany). Goat serum 
(Vector Labs) 10% was applied for 30 min. after this, sections were incubated overnight at 4 °C in 
biotinylated Lectin antibody (Isolectin B4 Biotin labeled, Sigma Aldrich, Munich, Germany; 1:270 in 
TRIS buffer). The day after, detection was carried out using streptavidin AB Complex/HRP (Dako 
GmbH, Hamburg, Germany) for 30 min, washed, followed by development with DAB+ chromogen 
(Dako GmbH, Hamburg, Germany) 10 min. Counterstaining was performed with 1:10  
Hematoxylin solution.  
ED1 (CD68). ED1 is a monoclonal antibody that binds to the rat homologue of human CD68, a  
90–110 kDa protein found on macrophages and monocytes [24]. For this staining, sections were 
dewaxed and cooked at 121 °C for 1 min. After cooling, a blocking solution (Zytochem Plus AP 
Polymer Kit, Zytomed Systems, Berlin, Germany) was applied for 5 min to minimize background 
staining. Slides were incubated overnight at 4 °C in primary antibody solution (monoclonal mouse 
anti-rat CD68, Serotec, Düsseldorf, Germany; 1:300). The next day, enhancement reagent (Zytochem 
Plus AP Polymer Kit) was applied for 30 min, followed by an AP coupled secondary antibody  
(anti-mouse/anti-rabbit, 30 min). Development was carried out using Fast Red solution for 20 min, and 
Hemalaun solution was used for counterstaining. 
Images were using an Olympus IX81 microscope (Olympus, Hamburg, Germany) and Digital 
Camera under 4×, 10× or 20× magnification. Cell proliferation was analyzed by counting of 
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fluorescence stained cell nuclei using a standardized threshold (ImageJ, National Institutes of Health, 
Bethesda, Md.). 
Statistics. Statistical analysis of mitochondrial and LDH activity of MSCs and cell number was 
accomplished by one-way analysis of variance (ANOVA) on the different hydrogel films after 48 h of 
incubation. The pairwise comparison of the means was performed with the Bonferroni’s test (post hoc 
comparison). P-values < 0.05 were considered statistically significant. 
3. Results 
3.1. In vitro Evaluation of Biocompatibility 
3.1.1 Cell Viability 
The viability of the rat bmMSCs on alginate, alginate dialdehyde-gelatin (ADA-GEL) and alginate 
dialdehyde-gelatin-nano-Bioglass® (ADA-GEL-nBG) hydrogels after 48 h of incubation was 
investigated by analyzing the mitochondrial and LDH activities, as presented in Figure 2.  
Figure 2. Mitochondrial and LDH activities of rMSCs on alginate, ADA-GEL and  
ADA-GEL-nBG hydrogel films after 48 h of cultivation. Alginate was used as the control 
material for each assay. Asterisks denote significant difference compared to alginate 
hydrogel, *p < 0.05, **p < 0.01 and ***p < 0.001 (Bonferroni’s post-hoc test was used). 
 
Mitochondrial activity of MSCs for ADA-GEL and ADA-GEL-nBG hydrogels was found to be 
significantly higher compared to that for the control material, alginate, with 1.5 and 1.3 times 
increased for ADA-GEL and ADA-GEL-nBG, respectively. A similar trend was observed for LDH 
activity of MSCs, where LDH activity for ADA-GEL and ADA-GEL-nBG was found to be 1.9 and 
1.7 folds increased compared to alginate.  
3.1.2. Cell Morphology 
Actin cytoskeleton staining of MSCs was performed to visualize overall prospective of cell 
morphology and cell spreading on the hydrogels (see Figure 3). A high number of cells on ADA-GEL 
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and ADA-GEL-nBG hydrogels was evident, compared to alginate. On alginate films, cells were 
agglomerated and formed clusters after 48 h. On ADA-GEL, cells were spread in flat shape and 
interacted with each other in high contact area. On ADA-GEL-nBG, cells looked elongated and 
transformed to spindle shape.  
Figure 3. FM images of MSCs adhered on (a) alginate; (b) ADA-GEL; and  
(c) ADA-GEL-nBG hydrogel films after 48 h of cultivation. The cells were stained for 
actin (red) and nucleus (green). 
 
3.1.3. Cell Proliferation 
Cell proliferation was analyzed after 48 h of cultivation and presented as number of cells per unit 
area of hydrogel films. As seen in Figure 4, the number of cells on ADA-GEL and ADA-GEL-nBG 
was significantly increased compared to alginate. The number of cells for ADA-GEL and ADA-GEL-nBG 
was found to be 1.8 and 1.4 folds increased compared to that for alginate, thus showing a similar 
pattern as mitochondrial and LDH activities. 
Figure 4. Number of cells per unit area of alginate, ADA-GEL and ADA-GEL-nBG 
hydrogel films after 48 h of cultivation. Alginate was used as the control material. 
Asterisks denote significant difference compared to alginate hydrogel, *p < 0.05,  
**p < 0.01 and ***p < 0.001 (Bonferroni’s post-hoc test was used). 
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3.2. In vivo Subcutaneous Implantation of Microcapsules 
3.2.1. Clinical Evaluation 
All animals tolerated anesthesia and the surgical procedure well, and no rat showed signs of 
discomfort after surgery. A mild to moderate seroma surrounding the chambers was commonly 
observed, but resolved spontaneously after approximately one week. A strong inflammatory reaction 
could not be seen, and all animals gained weight and showed good general welfare. 
3.2.2. Macroscopic Appearance  
At the time of explantation, two constructs of the 4 weeks ADA-GEL-nBG group appeared infected 
and were excluded from the study. One chamber was displaced subcutaneously, so that microcapsules 
did not have reliable contact with the underlying muscle; this construct was also excluded. 
After 1 week, microcapsules were soft, moist and loosely attached to the surrounding tissue  
(Figure 5a,b). Leakage of India ink solution from vessels was common. After four weeks, 
microcapsules were more adherent, and no leakage of India ink solution occurred. Microcapsules in 
deeper layers were firm and often macroscopically dry (Figure 5c,d).  
Figure 5. Macroscopic appearance after explantation. (a) ADA-GEL, 1 week;  
(b) ADA-GEL-nBG, 1 week; (c) ADA-GEL, 4 weeks; (d) ADA-GEL-nBG, 4 weeks. 
Microcapsules were moist and loosely adherent after 1 week (a,b) and well adherent, but 
often dry after 4 weeks (c,d). 
 
3.2.3. Microscopic Appearance 
(1) Cellular infiltration, degradation 
After one week, microcapsules had maintained their original shape and were surrounded by a thin 
layer of granulation tissue. A beginning cellular infiltration could be seen in some microcapsules.  
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After 4 weeks, the connective tissue surrounding the microcapsules was more prominent. 
Microcapsules directly adjacent to the muscle were of similar shape than microcapsules after 1 week; 
cellular infiltration was mild in most cases, but had proceeded to the center of the microcapsules 
(Figure 6a). A thin gap between microcapsules and surrounding connective tissue/muscle could be 
seen in several sections. More distant microcapsules had lost their original shape and appeared 
homogenously eosinophilic. After 4 weeks, ingrowth of connective tissue into single microcapsule was 
visible (Figure 6b). 
Figure 6. HE staining after 4 weeks; (a) ADA-GEL group; (b) ADA-GEL-nBG group; 10×. 
(a) Mild cellular infiltration had proceeded to the center of microcapsules. A thin gap 
between the capsule and the surrounding connective tissue was common (arrow).  
(b) Ingrowth of connective tissue into single microcapsule was visible (arrows). 
 
(2) Immune reaction 
A moderate number of ED1 positive cells were detectable in the connective tissue after 1 week, and 
some ED1 positive cells could be seen within single microcapsule (Figure 7a). However, this finding 
was not consistent. No foreign-body giant cells were observed at this time point. 
Figure 7. ED1 staining after (a) 1 week (ADA-GEL group), 10×; (b) 4 weeks  
(ADA-GEL-nBG group), 10×; (c) after 4 weeks (ADA-GEL-nBG group), 20×. (a) Grade 
of infiltration of microcapsules with ED1 positive cells was inconsistent; (b) ED1 positive 
cells were limited to areas directly adjacent to microcapsules after 4 weeks (arrow); (c) 
Single foreign body giant cells were detected after 4 weeks (arrow). 
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After 4 weeks, ED1 positive cells in the connective tissue were limited to the area directly adjacent 
to the microcapsules (Figure 7b). Infiltration of microcapsules was inconsistent. Some foreign body 
giant cells could be detected, with no difference between constructs with and without nBG (Figure 7c). 
(3) Vascularization 
Some Lectin positive cells were detected within the microcapsules after 1 and 4 weeks. As with 
ED1 positive cells, this was considered an inconsistent finding. 
After 4 weeks, immunohistochemical staining showed Lectin positive tubular structures in spaces 
between microcapsules, which might be a sign of ongoing vessel formation (Figure 8a). In 
microcapsules with connective tissue ingrowth, formation of such tubular structures could be detected 
also within the microcapsules (Figure 8b). However, not all of these structures were filled either with 
India Ink or with erythrocytes, which might question their functionality at this time point. 
Figure 8. Lectin staining after four weeks (ADA-GEL-nBG group), 20×; (a) ED1 positive 
cells forming tubular structures were common in the connective tissue between the 
microcapsules (arrow); (b) formation of lectin positive tubular structures in microcapsules 
with connective tissue ingrowth (arrows).  
 
4. Discussion 
Good cell viability and proliferation, as shown by increased mitochondrial and LDH activities, were 
found on ADA-GEL films and, albeit less pronounced, on ADA-GEL-nBG films, when compared to 
the control hydrogel, alginate. The increase of the mitochondrial and LDH activities of MSCs on  
ADA-GEL hydrogel compared to alginate can be explained by the high biodegradability and the RGD 
(Arg-Gly-Asp) sequence (specific cell adhesive peptide) of gelatin [25,26]. Furthermore, ADA is an 
oxidized product of alginate, which provides high degradability because of its low molecular  
weight [27]. Degradation of hydrogel enhances the mesh size and permits cell anchoring  
and penetration.  
Mitochondrial and LDH activities of MSCs on ADA-GEL-nBG were found to be lower than on 
ADA-GEL. A possible explanation is a cytotoxic effect due to released ions from nBG  
particles [21,28]. However, this would be in contrary to results found when using rat osteoprogenitor 
cells, where nBG stimulated proliferation and RunX2 synthesis [20]. Osteogenic differentiation of 
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MSCs would be another possible mechanism of changed metabolism, although it seems unlikely after 
only 48 h. Staining protocols such as Alizarin Red, ALP or von Kossa staining, trilineage 
differentiation experiments and flow cytometry of MSCs grown on ADA-GEL and ADA-GEL-nBG 
films should show their differentiation status and progenitor potential in future experiments. 
Different morphologies were observed after 48 h of cultivation. On alginate films, cells were 
agglomerated and formed clusters after 48 h. Here cell-cell interactions seem to be superior to  
cell-material interactions, which induce the agglomeration of cells due to a lack of cell adhering 
biomolecules in alginate [29]. On ADA-GEL films, cells spread nicely and interacted with each other, 
suggesting suitable conditions for MSC growth. On ADA-GEL-nBG films, cells were elongated and 
transformed to spindle shape. Again, the released ions from nBG particles could have an effect on cell 
morphology, either by cytotoxic mechanisms or by induction of osteogenic differentiation. It is known 
that MSC phenotypic expression can be influenced both by soluble and by insoluble factors, such as 
ECM density and stiffness [30].  
A mild to moderate seroma surrounding the chambers was common and resolved spontaneously 
after approximately one week. This reaction was most likely provoked by the teflon chamber itself, 
rather than the microcapsules, since this happened with several materials tested in similar experiments 
by our group. A strong inflammatory reaction could not be seen, despite the lack of anti-inflammatory 
treatment postoperatively, and all animals gained weight and showed good general welfare. This 
confirms the good clinical biocompatibility of this material. Leakage of India Ink after 1 week was 
probably due to low stability of newly formed vessels at this time point. 
Degradation is a crucial factor in tissue engineering. The scaffold degradation rate should ideally 
match the rate of new tissue production [31]. Under good conditions, beginning bone formation can be 
achieved in rats as early as 2 weeks using osteoinductive and osteoconductive scaffolds [32]. In this 
study, a thin gap was seen between microcapsules and surrounding connective tissue in several slides 
from both 4-weeks-groups, and ingrowth of connective tissue into single microcapsule was visible. 
This would ideally match the rate of new bone formation that can be achieved in these animals. 
Gelatin can be completely degraded in vivo by various enzymes, such as MMP-2 (Gelatinase A) or 
MMP-9 (Gelatinase B) [33]. Contrary to this, the in vivo degradation of pure alginate has been 
described as uncontrollable and unpredictable due to lack of natural enzymes for alginate degradation 
in mammals [8]. Oxidation is therefore often performed prior to crosslinking [6], as used in this study, 
to allow for hydrolytic in vivo degradation of the product. Furthermore, oxidized alginate molecules 
are easily be eliminated by the kidneys, in contrary to pure alginate molecules [34]. The combination 
of easily degradable gelatin and oxidized alginate is not expected to create any products that cannot be 
eliminated in vivo during degradation and did in fact not cause any clinical problems in this study.  
The diffuse infiltration of connective tissue with ED1 positive cells seen after 1 week was probably 
more related to general inflammation after surgery than to the implanted material itself. After 4 weeks, 
ED1 positive cells were still present in a comparable number, but localized more adjacent to 
microcapsules, thus showing a reaction specifically induced by the implanted material. A possible 
explanation is the role of macrophages in degradation of the implanted matrix, such as by secreting 
MMP-2 and MMP-9 [35]. The low number of foreign body giant cells points to a good overall 
acceptance of the implanted matrix and is in accordance with previous studies evaluating the immune 
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reaction to both gelatin [9] and alginate [4] in vivo. Contrary to our in vitro results, the addition of nBG 
to these materials does not seem to have any influence on their in vivo biocompatibility.  
One of the most challenging problems in tissue engineering, especially when aiming at large,  
three-dimensional constructs is the need for adequate and rapid vascularization, since diffusion of 
nutrients and oxygen can occur only up to a distance of 200–300 µm [36]. Under ischemic conditions 
(low oxygen and, more importantly, low glucose), MSC viability and adenosine 5ʹ-triphosphate (ATP) 
content decreases after approximately six days [37]. The presence of Lectin positive tubular structures 
between microcapsules in this study shows ongoing angiogenesis. However, nutrition was apparently not 
sufficient for deeper layers, since microcapsules situated more distant from muscular tissue and thus from 
nutrient vessels were often dry and had lost their original shape after 4 weeks. For large constructs, axial 
vascularization [38–41], the addition of growth factors to the hydrogel [42] and encapsulation of 
endothelial cells [43] might be a possibility to improve blood supply to the center. Furthermore, 
fibroblasts incorporated into alginate beads with bioactive glass have shown to produce a significant 
amount of VEGF [44]. VEGF increases endothelial cell survival, proliferation and migration and 
therefore typically mediates the first phase of capillary ingrowth [45]. Similar results might be 
obtained by encapsulating mesenchymal stem cells, and might also stimulate osteogenesis at the  
same time [4]. 
No differences in any of the described microscopic parameters could be seen between ADA-GEL 
and ADA-GEL-nBG microcapsules after subcutaneous implantation. Nano-scaled bioactive glass 
particles have been recently introduced in bone tissue engineering, with promising results in in vitro 
experiments. When combined with biodegradable polymers, nano-scaled particles should mimic the 
nano-features of the mineral phase of bone and thus increase cell adhesion and proliferation of 
osteogenic cells [46,47]. Several cytocompatibility studies confirmed good cell attachment and 
proliferation when used with different cell types [21,28,48,49]. Only a few studies have been evaluated 
biocompatibility of nBG particles in vivo [49,50] and found similar results as seen with larger 
bioactive glass particles [51]. The good in vivo biocompatibility was seen in the current study is in 
accordance with these results; however, our in vitro results suggest a cytotoxic effect of nBG on MSCs 
directly in contact with the material. Future studies should focus on cell survival, proliferation and 
differentiation potential of encapsulated cells both in vitro and in vivo as well as on determination of 
the ideal nBG concentration for bone tissue engineering applications. 
5. Conclusions and Future Work 
The current study shows good biocompatibility of ADA-GEL hydrogels both with and without 
nano-scaled bioactive glass (45S5) particles. In vitro experiments showed good proliferation after 
seeding on films and an increase of mitochondrial and LDH activities. However, the addition of nBG 
seemed to exhibit some inhibiting effect compared to pure ADA-GEL. In vivo implantation did not 
show a significant immune reaction, and ongoing degradation of the materials after four weeks was 
apparent, which would ideally match beginning bone formation in rats after this time. Ongoing 
vascularization could be seen after four weeks. No difference could be observed between pure  
ADA-GEL and ADA-GEL-nBG microcapsules. In conclusion, the tested materials show favorable 
properties for future applications in bone tissue engineering. 
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